Etienne-Emile Baulieu, the discoverer of neurosteroids, and a panel of distinguished scientists and clinical researchers exhaustively and critically review all facets of neurosteroids involved in behavior, stress, memory, depression, anxiety, aging of the brain, and neurodegenerative diseases. These contributors illuminate the role of neurosteroids in brain development and plasticity and detail their neuromodulatory influence on GABAA, ionotropic glutamate receptors, acetylcholine receptors, sigma receptors, and calcium channels. Clearly pointing the way toward novel pharmaceutical agents that may be of significant therapeutic value, particularly with regard to aging mental functions, Neurosteroids: A New Regulatory Function in the Nervous System offers neurobiologists, psychiatrists, neurosurgeons, pharmacologists, and geriatricians the first comprehensive, state-of-the-art review of these important bioactive molecules.

Part B explores protein degradation occuring in vivo during protein synthesis in cells, examines the isolation and purification of proteins, details protein use in organisms, and reviews techniques to enhance protein stability.

The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect.

This detailed volume examines computer-aided drug discovery (CADD), a crucial component of modern drug discovery programs that is widely utilized to identity and optimize bioactive compounds for the development of new drugs. With a focus on the methods that are commonly used in the early stage of drug discovery, chapters explore computer simulation, structure prediction, conformational sampling, binding site mapping, docking and scoring, in silico screening, and fragment-based drug design. In addition to the state-of-the-art theoretical concept, this book also includes step-by-step, readily reproducible computational protocols as well as examples of various CADD strategies. The limitations and potential pitfalls of different computational methods are discussed by experts, and tips and advice for their applications are suggested. Practical and thorough, Computer-Aided Drug Discovery serves as an ideal addition to the Methods in Pharmacology and Toxicology series, guiding researchers toward their lab's goals with this exciting and versatile technology.

At the Mie International Symposium held in Japan in April 1994, leading scientists reviewed recent advances in the understanding of the contractile mechanism in smooth muscle. The present volume collects the papers presented at the symposium, summarizing the latest advances in smooth muscle function and emphasizing important components of the contraction-relaxation cycle. Topics include a discussion of the smooth muscle cell membrane, with emphasis on its ion channels; the regulation of cytosolic Ca2+ levels and the relationship to force in smooth muscle; aspects of the two key regulatory enzymes involved with myosin phosphorylation-dephosphorylation; the molecular basis for pharmacomechanical coupling in smooth muscle; developments in the basic contractile mechanisms involving the crossbridge cycle of tonic and phasic muscle; the role of myosin light chains; and many others. The approach is broad and presents contemporary opinions in pharmacology, physiology, and biochemistry as they relate to smooth muscle function. The book will appeal not only to those working in these disciplines, but to vascular clinicians, obstetric-gynecological physicians, and gastroenterologists as well.

Nanoengineering, energized by the desire to find specific targeting agents, is leading to dramatic acceleration in novel drug design. However, in this flurry of activity, some issues may be overlooked. This is especially true in the area of determining dosage and evaluating the effects of multiple agents designed to target more than one site of metastasis. Offering the unique perspective of a medical physicist who has worked directly with cancer patients for over three decades, Radiopharmaceuticals: Introduction to Drug Evaluation and Dose Estimation starts by exploring the recent history and current state of the field. Then, citing key research and practical examples, the author looks at how to run studies and employ estimation and evaluation methods that lead to the best multiple agents with the least amount of trial and error. He discusses methods that will allow researchers to more rigorously: Differentiate one radiopharmaceutical (RP) from another Estimate radiation doses Correlate results across various species to realize more informed data from clinical trials Incorporating developments in nanotechnology and radiology, with the ultimate goal of achieving personalized patient-specific treatment, this book crosses disciplines to addresses a range of topics including: Preclinical RP development Organization of clinical trials Determination of activity in vivo Modeling and temporal integration with a look at the mass law for tumor uptake as a function of tumor size (discovered by the author) Absorbed dose estimates with and without clinical correlations Multiple-modality therapy Dr. Lawrence Williams has devoted most of his life's research to tumor detection and treatment, and his discoveries continue to influence evolving therapies. As s a medical physicist, he is eminently qualified to bring unique insight into the discussion of radiopharmaceutical dosage rates and efficacy.

This detailed volume aims to introduce nanomaterials as a new therapeutic regimen in treating human diseases. Divided into four sections, it explores inorganic nanomaterials, organic nanomaterials, pharmaceutical properties of nanomaterials, and applications of nanomaterials in medicine. Several examples of inorganic and organic nanomaterials are provided to demonstrate how to design and develop nanomaterials for pharmacological purposes. The key pharmaceutical properties, including biocompatibility, tissue interaction, pharmaceutics, and pharmacokinetics of nanomaterials are discussed with a focus on the safety and pharmaceutical considerations of nanomaterials in translational development. The pharmacological applications of nanomaterials are depicted in treating various human diseases, including cancer, cardiovascular diseases, immune disorders, infectious diseases, gastrointestinal disorders, bone diseases, respiratory disorders, and drug delivery. Written for the Methods in Pharmacology and Toxicology series, chapters include the kind of specifics and practical advice that ensures a smooth transition into the lab. Authoritative and enlightening, Nanomaterials in Pharmacology serves as an ideal guide to researchers investigating the potential benefits and risks of nanomaterials in pharmacology in order to avoid the pitfalls and to maximize the potential of this vital field of study.

By the year 2050, the world's population is expected to reach nine billion. To feed and sustain this projected population, world food production must increase by at least 50 percent on much of the same land that we farm today. To meet this staggering challenge, scientists must develop the technology required to achieve an "evergreen" revolution -- one that increases crop productivity without degrading natural resources. With 30 percent new material, the updated and revised third edition of Growth and Mineral Nutrition of Field Crops covers all aspects of crop growth and mineral nutrition that contribute to sustainable, high-yield agriculture. Bringing together international scientific knowledge of crop production and the impacts of agriculture on the environment, this book: * Includes two new chapters on remediation of heavy-metal contaminated soils and cover crops * Covers theoretical and practical aspects of mineral nutrition of field crops * Provides recommendations for judicious use of fertilizers, which will reduce cost of crop production and enhance high crop yields without risking environmental pollution * Provides growth patterns for annual crops and forages * Includes a handful of color pictures of nutrient deficiencies for easy diagnostic purposes To make the book as practical as possible, each chapter is supported by experimental results and extensive references. A large number of figures and tables are also included to save readers time when researching. The overall emphasis of this reference is on the soil's ability to sustain high crop yields and a healthy human population.

This book covers new techniques in protein NMR, from basic principles to state-of-the-art research. It covers a spectrum of topics ranging from a "toolbox" for how sequence-specific resonance assignments can be obtained using a suite of 2D and 3D NMR experiments and tips on how overlap problems can be overcome. Further topics include the novel applications of Overhauser dynamic nuclear polarization methods (DNP), assessing protein structure, and aspects of solid-state NMR of macroscopically aligned membrane proteins. This book is an ideal resource for students and researchers in the fields of biochemistry, chemistry, and pharmacology and NMR physics. Comprehensive and intuitively structured, this book examines protein NMR and new novel applications that include the latest technological advances. This book also has the features of: * A selection of various applications and cutting-edge advances, such as novel applications of Overhauser dynamic nuclear polarization methods (DNP) and a suite of 2D and 3D NMR experiments and tips on how overlap problems can be overcome * A pedagogical approach to the methodology * Engaging the reader and student with a clear, yet critical presentation of the applications

Contents. List of Contributors. Preface. T.J. Mitchell and T.J. Williams: The role of eotaxin and related CC-chemokines in asthma and allergy. Roger J. Davis: Signal transduction by the JNK group of MAP kinases. Marie Chabot-Fletcher: TNF and IL-1 signaling to NF-kB. Anthony M. Manning: Small molecule regulators of AP-1 and NF-kB. Robert T. Abraham: Mammalian target of rapamycin: Immunosuppressive drugs offer new insights into cell growth regulation. Catherine A. Burton, John Boylan, Candy Robinson, Janet Kerr and Pamela Benfield: Constitutive expression of a tumor suppressor leads to tumor regression in a xenograft model. Steven D. Shapiro: Macrophage metalloproteinases in destructive inflammatory diseases. Nancy H. Ruddle: Lymphotoxin in inflammation and lymphoid organ development: Variations on a theme. Steven L. Kunkel, Sem H. Phan, Nicholas W. Lukacs, Cory Hogaboam and Stephen W. Chensue: Chemokine/cytokine biology during the evolution of fibrotic disease. Long Gu, Susan C. Tseng and Barrett J. Rollins: The role of MCP-1 in disease. Lisa A. Beck, Cristiana Stellato, Syed Shahabuddin, Renate Nickel and Robert P. Schleimer: The role of chemokines in allergic diseases of the airways. James Winkler and Ken Tramposch (coordicators): Ninth International Conference of the Inflammation Research Association, November 1-5, 1998: Summaries of workshops and poster discussions. William Williams and Elizabeth Arner (chair persons): Targets in rheumatoid and osteoarthritis. Lawrence Wennogle and Nancy Cusack (chair persons): Signal transduction and regulation of gene expression. James Burke and Floyd Chilton (chair persons): Mediators in inflammation and their enzymes. Denis Schrier and Fandrew Issekutz (chair persons): Cell adhesion molecules and leukocyte trafficking. Robert M. Strieter and David Underwood (chair persons): Pulmonary inflammation, fibrosis, and disease. W. Hunter and E. Turley (chair persons): Angiogenesis, wound repair and skin inflammation. Index.

Recombinant proteins and polypeptides continue to be the most important class of biotechnology-derived agents in today's pharmaceutical industry. Over the past few years, our fundamental understanding of how proteins degrade and how stabilizing agents work has made it possible to approach formulation of protein pharmaceuticals from a much more rational point of view.

This book describes the current level of understanding of protein instability and the strategies for stabilizing proteins under a variety of stressful conditions.

Influenza continues to be an ongoing problem despite the existence of vaccines and drugs. Disease outbreaks can occur relatively quickly as witnessed with the recent emergence of the influenza virus A/H1N1 pandemic. The development of new anti-influenza drugs is thus a major challenge. This volume describes all aspects of the virus structure and function relevant to infection. The focus is on drug discovery of inhibitors to the enzyme sialidase, which plays a key role in the infectious lifecycle of the virus. Following an overview of the influenza virus, the haemagglutinin, the interactions with the cell receptors and the enzymology of virus sialidase, recent results in drug design are presented. These include a full coverage of the design, synthesis and evaluation of carbohydrate as well as non-carbohydrate influenza virus sialidase inhibitors. Further reviews of the clinical experience with influenza virus sialidase inhibitors and of the development of resistance to these inhibitor drugs complement the topic.

Investigation of the pharmacokinetics and metabolism of human proteins has escalated over the last two decades because of the use of recombinant human proteins as therapeutic agents. In addition, the development and improvement of analytical techniques enabling the detection of minute quantities of proteins in biological matrices have aided this process. In assembling this volume, we sought to provide a state-of-the-art as sessment of the pharmacokinetics and metabolism of protein therapeutics through complete reviews of selected examples. A comprehensive review of all protein therapeutics was not attempted; the majority -of the therapeutic protein classes and crucial scientific issues have been addressed, however. Therefore, we are confident that this volume will provide a useful reference for scientists in this field. The volume has been divided into two general parts. The first part (Chapters 1-3) is composed of general reviews of topics of importance in pharmacokinetic/metabolism studies of proteins: goals and analytical meth odologies, effects of binding proteins, and effects of antibody induction, respectively. The second part (Chapters 4-8) consists of specific, detailed reviews by therapeutic protein class: growth factors and hormones, cyto kines, cardiovascular proteins, hematopoietic proteins, and antibodies, respectively. The editors are grateful to the contributors for the patience, personal sacrifice and perseverance required to complete this volume. BoDDE L. FERRAIOLO MARJORIE A. MOHLER CAROL A. GLOFF ix Contents Chapter 1 Goals and Analytical Methodologies for Protein Disposition Studies Bobbe L. Ferraiolo and Marjorie A. Mohler 1. Introduction ................................................. ."

A comprehensive review of the science of drug testing in all its aspects, placing emphasis on technologies that use body fluids other than urine for determining the presence of drugs of abuse. The authors discuss the various body fluid specimens suitable for testing for illicit drugs-particularly saliva, sweat, and hair-describe the structural and manufacturing aspects of on-site testing devices based on lateral flow immunoassay, and detail the pitfalls of using these specimens. They also discuss in detail the problem of sample adulteration and its detection. Since oral fluid has the best potential of succeeding urine as the next matrix of choice for drug detection, four popular saliva testing devices are examined: Intercept (R), the Drager Drug Test (R), Oratect (R), and Drugwipe. Political, social, and legal issues are also considered in articles on privacy, the use of drug testing in courts, and the problem of sample adulteration.

In a systematic and clear manner, the authors discuss the problems associated with clinical decision making and explore the current methods to solve them. In this monograph, they examine the results of combining the classical control system approach with the symbolic approaches which have been central to developments in artificial intelligence. Well illustrated with case studies, this volume will prove to be an invaluable resource to system scientists, engineers, computer scientists, and members of the medical community.

The Evidence-Based Guide to Antipsychotic Medications is designed to provide both clinicians and residents with focused, comprehensive, and clinically relevant information regarding the use of antipsychotic medications to treat a broad range of psychiatric conditions -- from mood and anxiety disorders to substance abuse, personality disorders, and schizophrenia.

The volume editor is a renowned psychiatrist and author with more than 25 years of experience in both clinical and research settings diagnosing and treating patients with mood and psychotic disorders. In addition, each of the volume's 13 contributors is an expert with many years of clinical experience to draw on.The book is down-to-earth and reader-friendly and is structured for maximal utility in both coverage and format: - Key Clinical Points cap each chapter, synthesizing and summarizing the knowledge you can take away, and serving both as a refresher for those using the book as a reference and as a study aid to master the material.- Both FDA-approved and off-label use of antipsychotic medications are addressed, reflecting the reality of clinical practice on the front lines.- Use of antipsychotic medications in both the pediatric and geriatric populations, a potentially controversial subject, is addressed in a nonsensational, straight-forward manner.- The Appendixes provide a wealth of information in tabular format, including drug tables (names, strengths, formulations, pharmacokinetics, and dosing); advice on initiating and monitoring antipsychotic medications; common side effects and their management; and special considerations for use during pregnancy and breastfeeding.

The Evidence-Based Guide to Antipsychotic Medications is the first in a new series that strives to take evidence-based psychiatry from gold standard to standard practice. Scientifically up-to-date and rigorous, yet accessible and easy to understand, this volume stands alone as an indispensable resource on the topic.

This volume presents research on current trends in chemical regulations - a fa- growing, complex, and increasingly internationalized field. The book grew out from a multidisciplinary research project entitled 'Regulating Chemical Risks in the Baltic Sea Area: Science, Politics, and the Media', led by Michael Gilek at Soedertoern University, Sweden. This research project involved scholars and experts from natural as well as social sciences, based at Soedertoern University, Swedish Royal Institute of Technology (KTH), Karolinska Institutet, and Umea University. The project group organized a multidisciplinary research conference on chemical risk regulations, held in Stockholm, August 15-17, 2007. Most of the contributions published in this book were, in draft form, first presented at this conference. The conference, like the ensuing edited volume, expanded the geographical focus beyond the Baltic Sea area to include wider European, and to some extent also global trends. Many thanks to all project colleagues and conference participants! We are very grateful for the generous financial support received from The Foundation for Baltic and East European Studies (OEstersjoestiftelsen), The Swedish Research Council Formas, and from Soedertoern University. Without this support the present book would not have been possible. Special thanks to all of our fellow contributors, all of whom have submitted to- cal papers based on high-quality research. Many thanks also to Tobias Evers, who assisted us with technical editing. Finally, we are grateful for the professionalism shown by our editors at Springer.

This new edition was recognized as a highly commended title by the British Medical Association at the 2017 BMA Medical Book Awards . Regarded by both students and instructors, Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 4th Edition , offers an integrated mechanism-based and systems-based approach to contemporary pharmacology and drug development. An easy-to-follow format helps first- and second-year students grasp challenging concepts quickly and efficiently. Each chapter presents a clinical vignette illustrating a therapeutic problem within a physiologic or biochemical system; followed by a discussion of the biochemistry, physiology, and pathophysiology of the system; and concluding with a presentation of the pharmacology of the drugs and drug classes that activate or inhibit the system by interacting with specific molecular and cellular targets. Chapters are integrated into sections that focus on organ systems and therapeutic areas of highest importance. Clear, concise illustrations highlight key points, and drug summary tables offer quick access to essential information. The Fourth Edition features: Comprehensive updates to all chapters, including recently approved drugs Nearly 40 popular and practical Drug Summary Tables with state-of-the-art information on clinical applications, serious and common adverse effects, contraindications, and therapeutic considerations A new chapter on drug transporters , and extensively revised information on drug-receptor interactions, pharmacodynamics, drug toxicity, and pharmacogenomics Key changes to Section 1: Fundamental Principles of Pharmacology, which now provides a comprehensive framework for material in all subsequent chapters Hundreds of meticulously updated and colorized illustrations , including many that are new or substantially modified to highlight new understanding of physiologic, pathophysiologic, and pharmacologic mechanisms

The Pope's Piano is a collection of three short fiction stories. The first two tales, "Violin Master" and "The Pope's Piano," have central music themes. Several cats are side characters in the last two stories. All three are best described as religious mysteries where strange, magical things happen that are best attributed to the workings of God.

The third story, "The Kitten with the Bent Ear," describes a college professor leading class discussions on important and difficult topics that affect our daily lives, like the death penalty, expensive medical procedures, abortion, immigration, and end-of-life medical decisions. Interspersed with the class discussion is the story of the professor's cats, including one with several deformities. In "The Kitten with the Bent Ear," the harsh and pragmatic decisions animals in the wild take is contrasted to what are man's options. This story will allow each of us to see all sides of controversial issues and help you solidify your thinking as to what are practical and just solutions.

The trilogy may bring the reader closer to God and let you enjoy the mysteries of life. With love and belief, anything is possible, even miracles.

This work describes the importance of tumor microenvironment in favouring tumor progression and angiogenesis. Under physiological conditions, angiogenesis is dependent on the balance of positive and negative angiogenic modulators within the vascular microenvironment and requires the functional activities of a number of molecules, including angiogenic factors, extracellular matrix proteins, adhesion molecules and proteolytic enzymes. In normal tissues, vascular quiescence is maintained by the dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli. Tumor angiogenesis is linked to a switch in the balance between positive and negative regulators, and mainly depends on the release by inflammatory or neoplastic cells of specific growth factors for endothelial cells, that stimulate the growth of the blood vessels of the host or the down-regulation of natural angiogenesis inhibitors. In particular, the inflammatory infiltrate may contribute to tumor angiogenesis, and there are many reports of associations between tumor inflammatory infiltrate, vascularity and prognosis. New therapeutic approaches have been developed with the aim to control tumor angiogenesis through targeting of different components of tumor microenvironment.

Volume 2 discusses the relationship between patient and caregiver in terms of structural and interactional determinants. The impact of provider characteristics on "compliance" and "adherence" is given especially noteworthy treatment. Each volume features extensive supplementary and integrative material prepared by the editor, the detailed index to the entire four-volume set, and a glossary of health behavior terminology.